Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Daniel Ambinder

Interventional & Structural Cards · UMSOM

View

Dr. Amit Goyal

Interventional & Structural Cards · UT Southwestern

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Jennifer Rymer

Interventional & Peripheral Cards · Duke University

View

Dr. Ami Bhatt

Adult Congenital Heart Disease · MGH

View

  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

    Mar 26, 2026DOI: 10.1056/nejmoa2507874Original ArticleNEJM

    Written by: Frank A. Sinicrope, M.D.Fang-Shu Ou, Ph.D.Dirk Arnold, M.D.Walter R. Peters, M.D.Robert J. Behrens, M.D.Christopher H. Lieu, M.D.Khalid Matin, M.D.Deirdre J. Cohen, M.D.Samara L. Potter, M.D.Andrew B. Nixon, Ph.D.Lisa A Kottschade, A.P.R.N., C.N.P.Emily Kathol, Pharm.D.Wendy L. Frankel, M.D.Ardaman Shergill, M.D.Dennis Hsu, M.D.Anke Reinacher-Schick, M.D.Paul Mehan, M.D.Philip J. Gold, M.D.Maged F. Khalil, M.D.Tyler Zemla, M.S.Clare Gatten, M.A.Eileen M. O’Reilly, M.D.Jeffrey A. Meyerhardt, M.D.

    Summary

    In a trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue.
    DCDr. David Cohen
    Leading Voice

    Dr. David Cohen

    Cardiology · Interventional Cardiology & Structural
    Cardiovascular Research Foundation
    davidc